Disc Medicine, Inc.
IRON
$0.96
Change (1 day)
$77.60
Year High
$25.60
Year Low
Categories
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
P/B ratio for Disc Medicine, Inc. (IRON)
P/B ratio as of 2023: 3.73
According to Disc Medicine, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.73. At the end of 2022 the company had a P/B ratio of 0.12.
P/B ratio history for Disc Medicine, Inc. from 2020 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.73 |
| 2022 | 0.12 |
| 2021 | -1.45 |
| 2020 | 4.25 |